Thus, even though compound 8 itself may not be the ideal drug candidateto progress for treatment of hyperaldosteronism, there are a number of sites outsidethe dihydropyridine-binding site where CaV1.2 and CaV1.3differ sufficiently to suggest that selective blockade is achievable. Here, CAV1 is linked to hyperaldosteronism.